MA
MCID: MGR028
MIFTS: 67

Migraine with or Without Aura 1 (MA)

Categories: Genetic diseases, Neuronal diseases

Aliases & Classifications for Migraine with or Without Aura 1

MalaCards integrated aliases for Migraine with or Without Aura 1:

Name: Migraine with or Without Aura 1 56
Migraine 56 12 74 25 53 29 54 6 42 15 62 39 32
Migraine Disorder 12 25 17
Migraine with or Without Aura, Susceptibility to, 1 56 13
Migraine Disorders 43 71
Migraine Variant 12 71
Common Migraine 25 54
Migraines 25 15
Migraine with or Without Aura 12
Headache Including Migraine 54
Migraine, Susceptibility to 6
Headache Migrainous 25
Disorder, Migraine 25
Headache Migraine 25
Migraine Headache 25
Migraine Syndrome 25
Classic Migraine 25
Mgau; Ma 56
Mgr1 56
Mgau 56
Ma 56

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant

Miscellaneous:
headache duration 4-72 hours
aggravated by physical activity
genetic heterogeneity, see, e.g., mgr2 , mgr3 , mgr4 , mgr5 , mgr6


HPO:

31
migraine with or without aura 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:6364
OMIM 56 157300
OMIM Phenotypic Series 56 PS157300
ICD9CM 34 346
MeSH 43 D008881
NCIt 49 C89715
SNOMED-CT 67 193030005 37796009
MedGen 41 C3887485
UMLS 71 C0042331 C0149931

Summaries for Migraine with or Without Aura 1

MedlinePlus : 42 What are migraines? Migraines are a recurring type of headache. They cause moderate to severe pain that is throbbing or pulsing. The pain is often on one side of your head. You may also have other symptoms, such as nausea and weakness. You may be sensitive to light and sound. What causes migraines? Researchers believe that migraine has a genetic cause. There are also a number of factors that can trigger a migraine. These factors vary from person to person, and they include Stress Anxiety Hormonal changes in women Bright or flashing lights Loud noises Strong smells Medicines Too much or not enough sleep Sudden changes in weather or environment Overexertion (too much physical activity) Tobacco Caffeine or caffeine withdrawal Skipped meals Medication overuse (taking medicine for migraines too often) Some people have found that certain foods or ingredients can trigger headaches, especially when they are combined with other triggers. These foods and ingredients include Alcohol Chocolate Aged cheeses Monosodium glutamate (MSG) Some fruits and nuts Fermented or pickled goods Yeast Cured or processed meats Who is at risk for migraines? About 12 percent of Americans get migraines. They can affect anyone, but you are more likely to have them if you Are a woman. Women are three times more likely than men to get migraines. Have a family history of migraines. Most people with migraines have family members who have migraines. Have other medical conditions, such as depression, anxiety, bipolar disorder, sleep disorders, and epilepsy. What are the symptoms of migraines? There are four different phases of migraines. You may not always go through every phase each time you have a migraine. Prodome. This phase starts up to 24 hours before you get the migraine. You have early signs and symptoms, such as food cravings, unexplained mood changes, uncontrollable yawning, fluid retention, and increased urination. Aura. If you have this phase, you might see flashing or bright lights or zig-zag lines. You may have muscle weakness or feel like you are being touched or grabbed. An aura can happen just before or during a migraine. Headache. A migraine usually starts gradually and then becomes more severe. It typically causes throbbing or pulsing pain, which is often on one side of your head. But sometimes you can have a migraine without a headache. Other migraine symptoms may include Increased sensitivity to light, noise, and odors Nausea and vomiting Worsened pain when you move, cough, or sneeze Postdrome (following the headache). You may feel exhausted, weak, and confused after a migraine. This can last up to a day. Migraines are more common in the morning; people often wake up with them. Some people have migraines at predictable times, such as before menstruation or on weekends following a stressful week of work. How are migraines diagnosed? To make a diagnosis, your health care provider will Take your medical history Ask about your symptoms Do a physical and neurological exam An important part of diagnosing migraines is to rule out other medical conditions which could be causing the symptoms. So you may also have blood tests, an MRI or CT scan, or other tests. How are migraines treated? There is no cure for migraines. Treatment focuses on relieving symptoms and preventing additional attacks. There are different types of medicines to relieve symptoms. They include triptan drugs, ergotamine drugs, and pain relievers. The sooner you take the medicine, the more effective it is. There are also other things you can do to feel better: Resting with your eyes closed in a quiet, darkened room Placing a cool cloth or ice pack on your forehead Drinking fluids There are some lifestyle changes you can make to prevent migraines: Stress management strategies, such as exercise, relaxation techniques, and biofeedback, may reduce the number and severity of migraines. Biofeedback uses electronic devices to teach you to control certain body functions, such as your heartbeat, blood pressure, and muscle tension. Make a log of what seems to trigger your migraines. You can learn what you need to avoid, such as certain foods and medicines. It also help you figure out what you should do, such as establishing a consistent sleep schedule and eating regular meals. Hormone therapy may help some women whose migraines seem to be linked to their menstrual cycle If you have obesity, losing weight may also be helpful If you have frequent or severe migraines, you may need to take medicines to prevent further attacks. Talk with your health care provider about which drug would be right for you. Certain natural treatments, such as riboflavin (vitamin B2) and coenzyme Q10, may help prevent migraines. If your magnesium level is low, you can try taking magnesium. There is also an herb, butterbur, which some people take to prevent migraines. But butterbur may not be safe for long-term use. Always check with your health care provider before taking any supplements. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Migraine with or Without Aura 1, also known as migraine, is related to familial hemiplegic migraine and migraine without aura, and has symptoms including seizures, tremor and back pain. An important gene associated with Migraine with or Without Aura 1 is NOTCH3 (Notch Receptor 3), and among its related pathways/superpathways is Thyroid hormone signaling pathway. The drugs Timolol and Levomilnacipran have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and cortex, and related phenotypes are photophobia and vomiting

Disease Ontology : 12 A brain disease that is characterized by moderate to severe headaches, nausea, extreme sensitivity to light and sound and intense unilaterial throbbing or pulsing.

Genetics Home Reference : 25 A migraine is a type of headache that typically causes intense, throbbing pain usually in one area of the head. People can experience migraines once a year to multiple times a week. A person is considered to have chronic migraines if they experience 15 or more headache days a month with eight of those days involving migraine headaches. Migraines typically first start during a person's teens to early twenties, but they can begin anytime from early childhood to late-adulthood. A migraine usually has three stages: the period leading up to the headache (known as the premonitory or prodromal phase), the migraine itself (the headache phase), and the period following the headache (known as the postdromal phase). The premonitory phase can start from several hours up to several days before the headache appears. In this phase, affected individuals can experience extreme tiredness (fatigue), concentration problems, and muscle stiffness in the neck. A wide variety of additional signs and symptoms can occur including excessive yawning, food cravings, irritability, depression, sensitivity to light, and nausea. About one-third of people with migraine experience a temporary pattern of neurological symptoms called an aura. An aura typically develops gradually over a few minutes and lasts between 5 and 60 minutes. Auras commonly include temporary visual changes such as blind spots (scotomas), flashing lights, and zig-zagging lines of color. Additional features of aura can include numbness, difficulty with speech and language, episodes of extreme dizziness (vertigo), and double vision. During an aura, affected individuals might experience abnormal sensations including tingling or numbness, usually of the hands or mouth. An aura usually starts within one hour of the start of a migraine. In some cases, an aura can occur without a subsequent migraine. In the headache phase, the pain may last from a few hours to a few days. Affected individuals tend to experience nausea, vomiting, dizziness, and sensitivity to light and sound in addition to headache. Some have changes in their vision or sensitivity to odors and touch. The postdromal phase usually lasts a few hours but can linger for more than a day. In this phase, the headache pain is gone but individuals can experience fatigue, drowsiness, decreased energy, concentration problems, irritability, nausea, or sensitivity to light. Affected individuals may also have brief episodes of head pain when moving their head. People with migraine, particularly women who have migraine with aura, have an increased risk of a type of stroke that is caused by a lack of blood flow to the brain (ischemic stroke), but this is a rare occurrence. There are many migraine disorders that usually include additional signs and symptoms. For example, familial hemiplegic migraine and sporadic hemiplegic migraine are characterized by migraine with associated temporary weakness that affects one side of the body (hemiparesis). Additionally, cyclic vomiting syndrome is a migraine disorder usually found in children that causes episodes of nausea and vomiting in addition to headaches.

OMIM : 56 Migraine is the most common type of chronic, episodic headache, as summarized by Featherstone (1985). One locus for migraine with or without aura (MGR1) has been identified on chromosome 4q24. Other loci for migraine have been identified on 6p21.1-p12.2 (MGR3; 607498), 14q21.2-q22.3 (MGR4; 607501), 19p13 (MGR5; 607508), 1q31 (MGR6; 607516), 15q11-q13 (MGR7; 609179), 5q21 (with or without aura, MGR8, 609570; with aura, MGR9, 609670), 17p13 (MGR10; 610208), 18q12 (MGR11; 610209), 10q22-q23 (MGR12; 611706), and the X chromosome (MGR2; 300125). Mutation in the KCNK18 gene (613655) on chromosome 10q25 causes migraine with aura (MGR13; 613656). A subtype of autosomal dominant migraine with aura (MA), familial hemiplegic migraine (FHM; see 141500), is caused by mutation in the CACNA1A gene (601011) on chromosome 19p13 (FHM1; 141500), by mutation in the ATP1A2 gene (182340) on chromosome 1q21 (FHM2; 602481), or by mutation in the SCN1A gene (182389) on chromosome 2q24 (FHM3; 609634). Another locus for FHM has been mapped to chromosome 1q31 (FHM4; see 607516). There is evidence that a polymorphism in the estrogen receptor gene (ESR1; 133430.0005) and a polymorphism in the TNF gene (191160.0004) may confer susceptibility to migraine. A polymorphism in the endothelin receptor type A gene (EDNRA; 131243.0001) may confer resistance to migraine. (157300)

NINDS : 53 The pain of a migraine headache is often described as an intense pulsing or throbbing pain in one area of the head. However, it is much more; the International Headache Society diagnoses a migraine by its pain and number of attacks (at least 5, lasting 4-72 hours if untreated), and additional symptoms including nausea and/or vomiting, or sensitivity to both light and sound. Migraine is three times more common in women than in men and affects more than 10 percent of people worldwide. Roughly one-third of affected individuals can predict the onset of a migraine because it is preceded by an "aura," visual disturbances that appear as flashing lights, zig-zag lines or a temporary loss of vision. People with migraine tend to have recurring attacks triggered by a number of different factors, including stress, anxiety, hormonal changes, bright or flashing lights, lack of food or sleep, and dietary substances.  Migraine in some women may relate to changes in hormones and hormonal levels during their menstrual cycle.  For many years, scientists believed that migraines were linked to the dilation and constriction of blood vessels in the head. Investigators now believe that migraine has a genetic cause.

PubMed Health : 62 About migraine: Migraine is not the same as the usual kind of headaches that most people have every now and then. A migraine attack starts suddenly with severe pain on only one side of your head. The pain is much worse than a normal headache and usually accompanied by other symptoms as well. But these headaches are only considered to be migraines if the typical symptoms have occurred at least five times. Migraines can greatly affect everyday life. Some people only get them occasionally, while others are knocked out by migraines on several days every month. Different types of medicine can help you cope with migraines.

Wikipedia : 74 A migraine is a primary headache disorder characterized by recurrent headaches that are moderate to... more...

Related Diseases for Migraine with or Without Aura 1

Diseases in the Migraine Without Aura family:

Migraine with or Without Aura 1 Migraine with or Without Aura 2
Migraine with or Without Aura 3 Migraine Without Aura 4
Migraine with or Without Aura 5 Migraine with or Without Aura 6
Migraine with or Without Aura 8 Migraine with or Without Aura 10
Migraine with or Without Aura 11 Migraine with or Without Aura 12
Migraine with or Without Aura 13

Diseases related to Migraine with or Without Aura 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1285)
# Related Disease Score Top Affiliating Genes
1 familial hemiplegic migraine 35.9 NOTCH3 MGR6 MGR5 CALCA CACNA1A ATP1A2
2 migraine without aura 35.5 TNF NOTCH3 EDNRA
3 sporadic hemiplegic migraine 35.3 CACNA1A ATP1A2
4 migraine, familial hemiplegic, 3 34.8 CACNA1A ATP1A2
5 familial or sporadic hemiplegic migraine 34.7 CACNA1A ATP1A2
6 migraine, familial hemiplegic, 2 34.6 CACNA1A ATP1A2
7 migraine with aura 33.8 NOTCH3 MGR5 MGR1 ESR1 EDNRA CALCA
8 cluster headache 33.4 CALCA CACNA1A
9 patent foramen ovale 32.2 NOTCH3 EDNRA ATP1A2
10 hemiplegia 32.2 CALCA CACNA1A ATP1A2
11 alternating hemiplegia of childhood 31.7 CALCA CACNA1A ATP1A2
12 headache 31.0 NOTCH3 EDNRA CALCA CACNA1A BRCA2 ATP1A2
13 bone resorption disease 31.0 TNF ESR1 CALCA
14 migraine, familial hemiplegic, 1 12.7
15 migraine with or without aura 13 12.7
16 migraine with brainstem aura 12.7
17 familiar or sporadic hemiplegic migraine 12.4
18 migraine with or without aura 8 12.4
19 migraine with or without aura 2 12.4
20 migraine with or without aura 12 12.4
21 migraine with aura 7 12.3
22 migraine with or without aura 6 12.3
23 migraine without aura 4 12.3
24 migraine with or without aura 10 12.3
25 migraine with or without aura 3 12.3
26 migraine with aura 9 12.3
27 migraine with or without aura 11 12.3
28 cyclic vomiting syndrome 12.2
29 mccune-albright syndrome 12.2
30 meconium aspiration syndrome 12.1
31 epilepsy, familial temporal lobe, 4 12.0
32 vasculopathy, retinal, with cerebral leukodystrophy 11.7
33 cerebral arteriopathy, autosomal dominant, with subcortical infarcts and leukoencephalopathy, type 1 11.7
34 handl syndrome 11.7
35 macrophage activation syndrome 11.6
36 trochleitis 11.6
37 episodic ataxia 11.5
38 hemicrania continua 11.5
39 visual snow syndrome 11.5
40 fibrous dysplasia/mccune-albright syndrome 11.5
41 sturge-weber syndrome 11.5
42 convulsions, familial infantile, with paroxysmal choreoathetosis 11.5
43 adenosylcobalamin deficiency 11.5
44 alternating hemiplegia of childhood 1 11.5
45 carotidynia 11.5
46 fibromyalgia 11.5
47 hemochromatosis, type 1 11.4
48 episodic ataxia, type 2 11.4
49 orthostatic intolerance 11.4
50 celiac disease 1 11.4

Comorbidity relations with Migraine with or Without Aura 1 via Phenotypic Disease Network (PDN):


Anxiety Esophagitis
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Migraine with or Without Aura 1:



Diseases related to Migraine with or Without Aura 1

Symptoms & Phenotypes for Migraine with or Without Aura 1

Human phenotypes related to Migraine with or Without Aura 1:

31 (show all 6)
# Description HPO Frequency HPO Source Accession
1 photophobia 31 HP:0000613
2 vomiting 31 HP:0002013
3 phonophobia 31 HP:0002183
4 nausea 31 HP:0002018
5 migraine with aura 31 HP:0002077
6 migraine without aura 31 HP:0002083

Symptoms via clinical synopsis from OMIM:

56
Neurologic Central Nervous System:
photophobia
phonophobia
migraine with aura
migraine without aura
headache is unilateral
more
Abdomen Gastrointestinal:
vomiting
nausea

Clinical features from OMIM:

157300

UMLS symptoms related to Migraine with or Without Aura 1:


seizures, tremor, back pain, headache, syncope, hemiplegia, pain, recurrent paroxysmal headache, nausea, chronic pain, sciatica, vertigo/dizziness, sleeplessness, scotoma, scintillating, hemicrania

MGI Mouse Phenotypes related to Migraine with or Without Aura 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.56 ATP1A2 BRCA2 CACNA1A CLCN1 EDNRA ESR1
2 muscle MP:0005369 9.23 ATP1A2 CACNA1A CAPN3 CLCN1 EDNRA ESR1

Drugs & Therapeutics for Migraine with or Without Aura 1

PubMed Health treatment related to Migraine with or Without Aura 1: 62

A lot of people who have migraines know from experience what helps them. This often involves lying down in a quiet and dark room and putting cool wet towels or cooling pads on the side of their head that hurts. Most people take medicine to get through attacks that are especially painful. Medications used for migraine attacks include, in particular, acetaminophen (paracetamol), non-steroidal anti-inflammatory drugs (NSAIDs) such as acetylsalicylic acid (the drug in medicines like Aspirin ), diclofenac or ibuprofen , as well as special migraine medications like triptans. Acetaminophen (paracetamol), acetylsalicylic acid and ibuprofen are available without a prescription, as are two of the triptan drugs. But before using medication yourself it’s a good idea to see a doctor to find out if the headaches are actually migraines . Using painkillers and migraine medication too often can itself make the headaches worse. For this reason, people are advised not to take painkillers and migraine medications on more than ten days per month.

Drugs for Migraine with or Without Aura 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 560)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Timolol Approved Phase 4 26839-75-8 5478 33624
2
Levomilnacipran Approved, Investigational Phase 4 96847-54-0
3
Milnacipran Approved, Investigational Phase 4 92623-85-3 65833
4
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
5
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
6
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
7
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
8
Dorzolamide Approved Phase 4 120279-96-1 5284549 3154
9
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
10
Dihydroergotamine Approved, Investigational Phase 4 6190-39-2, 511-12-6 10531
11
Frovatriptan Approved, Investigational Phase 4 158747-02-5 77992
12
Caffeine Approved Phase 4 58-08-2 2519
13
Eletriptan Approved, Investigational Phase 4 143322-58-1 77993
14
Almotriptan Approved, Investigational Phase 4 181183-52-8, 154323-57-6 123606
15
Epoprostenol Approved Phase 4 35121-78-9, 61849-14-7 5282411 5280427
16
Nadolol Approved Phase 4 42200-33-9 39147
17
Dinoprostone Approved Phase 4 363-24-6 5280360
18
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
19
Ticagrelor Approved Phase 4 274693-27-5 9871419
20
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
22
Ephedrine Approved Phase 4 299-42-3 9294
23
Pseudoephedrine Approved Phase 4 90-82-4 7028
24
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
25
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
26
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
27
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 5754
28
Hydrocortisone acetate Approved, Vet_approved Phase 4 50-03-3
29
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
30
Oxcarbazepine Approved Phase 4 28721-07-5 34312
31
Phenytoin Approved, Vet_approved Phase 4 57-41-0 1775
32
Lorazepam Approved Phase 4 846-49-1 3958
33
Salmon calcitonin Approved, Investigational Phase 4 47931-85-1 16129616
34
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
35
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
36
Polyestradiol phosphate Approved Phase 4 28014-46-2
37
Nortriptyline Approved Phase 4 72-69-5 4543
38
Flunarizine Approved Phase 4 52468-60-7 941361
39
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
40
Verapamil Approved Phase 4 52-53-9 2520
41
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
42
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
43
Ferrous fumarate Approved Phase 4 141-01-5
44
Norethindrone Approved Phase 4 68-22-4 6230
45
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
46
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
47
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
48
Donepezil Approved Phase 4 120014-06-4 3152
49
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
50
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244

Interventional clinical trials:

(show top 50) (show all 1322)
# Name Status NCT ID Phase Drugs
1 Nutritional Based Protocol to Balance Serotonin for the Prevention or Reduced Frequency/Duration/Intensity of Migraines Unknown status NCT00363506 Phase 4
2 IM Ketorolac vs Diclofenac Potassium Powder for Oral Solution (Cambia) for the Acute Treatment of Severe Migraine Unknown status NCT02664116 Phase 4 Diclofenac postassium powder for oral solution and placebo injection;Ketorolac intramuscular injection and placebo oral solution
3 A Prospective Trial to Evaluate the Effectiveness of Clopidogrel to Relieve Migraine With Right-to-left Shunt Unknown status NCT02938182 Phase 4 clopidogrel
4 Prevention of Menstrual Migraines: Effects of Estrogen Add-back During the HFI in Patients Using Continuous Oral Contraceptives. Unknown status NCT01251263 Phase 4 Estradiol or Placebo;Estradiol or Placebo
5 Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial Unknown status NCT03185130 Phase 4 Normal Saline 5mL;Normal Saline 20mL/kg;Prochlorperazine 0.15 mg/kg up to 10 mg IV;Diphenhydramine 1 mg/kg up to 50 mg IV
6 Open Label Study of Milnacipran in the Preventive Treatment of Episodic Migraine With and Without Aura and Chronic Migraine. Unknown status NCT01319825 Phase 4 milnacipran
7 Transcutaneous Suboccipital Neurostimulation for the Treatment of Chronic Migraine Unknown status NCT02307071 Phase 4
8 Greater Occipital Nerve Blockade for the Treatment of Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
9 Double-Blind, Placebo Controlled Trial of Greater Occipital Nerve Block for the Treatment of Migraine Attacks Unknown status NCT03159000 Phase 4 Saline
10 A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Unknown status NCT01230411 Phase 4 Ibuprofen
11 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Gene Expression and Serum Levels of Some Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
12 Randomized Controlled Trial Evaluating the Additive Value of Intranasal Fentanyl on Ibuprofen in the Pain Management of Children With Moderate to Severe Headaches Unknown status NCT02638506 Phase 4 Fentanyl
13 Relationship Between Topiramate Use and Ocular Angle Status: A Prospective Pilot Study Unknown status NCT00153699 Phase 4 Topiramate
14 Neurologic Signatures of Chronic Pain Disorders Unknown status NCT02747940 Phase 4 flunarizine and/or pregabalin
15 Study Proposal - A Randomized Double-blinded Study Comparing Adding Etoricoxib Versus Placebo to Female Patients With Fibromyalgia-analysis of Organic and Psychiatric Measures Unknown status NCT00755521 Phase 4 etoricoxib
16 A Randomized Double-blinded Trial Comparing the Clinical Efficacy and Pharmacokinetic Parameters of Oral Diclofenac and Intramuscular Diclofenac in Patients With Acute Limb Injuries Unknown status NCT03472339 Phase 4 Diclofenac Sodium
17 Impact of Timolol/Dorzolamide Therapy on Autoregulation in Glaucoma Patients Unknown status NCT02053298 Phase 4 Timolol & Dorzolamide
18 A Multicenter, Double-blind, Randomized, Placebo-controlled, 4-Armed Parallel Group Study to Evaluate the Efficacy of Zolmitriptan 0.5-, 2.5- and 5-mg Nasal Spray in the Treatment of Acute Migraine Headache in Adolescents Completed NCT01211145 Phase 4 Placebo;Zolmitriptan;Zolmitriptan;Zolmitriptan
19 Prochlorperazine Verus Metoclopramide for the Treatment of Acute Migraine in the Emergency Department Setting Completed NCT00364806 Phase 4 Prochlorperazine;Metoclopramide
20 Open-label, 6 Month Crossover Study Evaluating Migraine Patient Satisfaction Comparing Treximet to 2 Aleve and 100mg Imitrex Taken Concomitantly Completed NCT01450995 Phase 4 Treximet;Imitrex and two Aleve
21 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
22 A Multicentre, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of Eletriptan 40 Mg for the Treatment of Migraine (With or Without Aura) in Subjects Unsuccessfully Treated With NSAIDS Completed NCT00634985 Phase 4 eletriptan
23 AXERT® Early miGraine Intervention Study (AEGIS): Efficacy and Safety of Almotriptan Malate (AXERT®) Versus Placebo for the Acute Treatment of Migraine Headache Completed NCT00210509 Phase 4 almotriptan malate
24 TOPAMAX (Topiramate) Intervention to Prevent Transformation of Episodic Migraine: The Topiramate INTREPID Study Completed NCT00212810 Phase 4 Topiramate
25 Clopidogrel On Top of Aspirin For the Prevention of New Onset Migraine Headache Occurrence Following Transcatheter Closure of Atrial Septal Defects: A Prospective Randomized Trial (the CANOA Study) Completed NCT00799045 Phase 4 Clopidogrel
26 Assessment of the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet Treatment on Blood Pressure When Administered Intermittently for Six Months for the Acute Treatment of Migraine Attacks, With or Without Aura, in Adults Completed NCT00792636 Phase 4 sumatriptan and naproxen sodium combination tablet;sumatriptan tablet;naproxen sodium tablet
27 A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia® (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years) Completed NCT02287376 Phase 4 Diclofenac Potassium for Oral Solution
28 Drug and Non-Drug Treatment of Severe Migraine Completed NCT00910689 Phase 4 Propranolol or nadolol;Placebo control;Optimal Acute Therapy
29 A Randomized, Double Blind, Controlled Versus Placebo in Parallel Groups, Study to Evaluate the Efficacy of 10 mg Lyophilized Oral Rizatriptan in the Acute Treatment of Migraine in Patients With Unilateral Trigeminal Autonomic Symptoms. Completed NCT00753311 Phase 4 rizatriptan or placebo
30 The Effects of Expectation and Knowledge on Rizatriptan and Placebo Treatment of Acute Migraine Headache Completed NCT00719134 Phase 4 Maxalt;placebo pill;placebo pills
31 An Open-label Study to Evaluate "Completeness of Response" Following Treatment With Treximet™ for Migraine Completed NCT00893737 Phase 4 sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
32 To Evaluate the Safety and the Efficacy of Tianshu Capsule Treating Migraine in a Randomized, Placebo-Controlled, Double-blind, Multicenter Study. Completed NCT02035111 Phase 4 Tianshu capsule;Sugar pill
33 Haldol/Diphenhydramine Versus Metoclopramide/Diphenhydramine for Treatment of Acute Headache in the Emergency Department: A Randomized Controlled Trial Completed NCT02098499 Phase 4 Haloperidol;Metoclopramide 10mg;Diphenhydramine
34 Corticosteroids for Acute Migraine. An ED-based, Randomized, Comparative Effectiveness Trial Completed NCT02847494 Phase 4 metoclopramide;Dexamethasone;methylprednisolone acetate
35 A Single Center Randomized Open-Label Two Arm Crossover Study of Subject Productivity Improvement and Satisfaction With Migraine Treatment Using Treximet vs Usual Triptan Completed NCT01086358 Phase 4 Triptan;Treximet 85Mg-500Mg Tablet
36 Comparison of Oral Paracetamol and Zolmitriptan Efficacy in the Treatment of Acute Migraine Headache in Emergency Department: Randomize Controlled Trial Completed NCT03145467 Phase 4 Paracetamol;Zolmitriptan
37 A Multicenter, Open-Label Study Using the MIDAS Questionnaire to Assess the Effect of Using the HCPC Guidelines for Migraine Management in Primary Care, Including the Use of Zomig-ZMT (Zolmitriptan) Orally Disintegrating Tablets 5.0mg and Zomig Nasal Spray 5.0mg as Indicated. Completed NCT00637286 Phase 4 Zolmitriptan
38 A Comparison of the Efficacy and Safety of ULTRACET® (Tramadol HCl/Acetaminophen) Versus Placebo for the Acute Treatment of Migraine Headache Pain Completed NCT00297375 Phase 4 tramadol HCl/acetaminophen
39 An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine Completed NCT01578941 Phase 4
40 AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain Completed NCT00212823 Phase 4 almotriptan malate
41 A Multicenter, Open-label Evaluation of Treatment Satisfaction, Tolerability, Safety and Preference for Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated With Triptans Completed NCT01016834 Phase 4 Sumatriptan
42 A Random Controlled Trial a Comprehensive Migraine Intervention at the Time of Discharge From the Emergency Department After Treatment for Acute Migraine Completed NCT01071317 Phase 4 Naproxen;Sumatriptan
43 Adequate Therapy of Topiramate in Migraine Completed NCT01060111 Phase 4 Topiramate Standard;Topiramate Slow;Propranolol booster
44 Diphenhydramine as Adjuvant Therapy for Acute Migraine. A Randomized Trial. Completed NCT01825941 Phase 4 metoclopramide;diphenhydramine;placebo
45 Effectiveness And Safety Of Frovatriptan For The Management (Acute Treatment)Of Menstrual Migraine Completed NCT00904098 Phase 4 Frovatriptan;Usual Care
46 Efficacy of Combination Therapy With Intravenous Ketorolac and Metoclopramide for Pediatric Migraine Therapy in the Emergency Department Completed NCT01596166 Phase 4 Ketorolac Tromethamine;Metoclopramide
47 A Single-Center, Open Label Pilot Study Examining The Use Of Duloxetine In The Prevention Of Episodic Migraine Completed NCT00443352 Phase 4 duloxetine
48 Does a Single Oral Dose of Dexamethasone After Successful Emergency Treatment of Migraine Reduce the Incidence or Severity of Rebound Headache Within 48 Hours? Completed NCT00216736 Phase 4 Dexamethasone;placebo
49 Efficacy of AXERT (Almotriptan Malate) in the Acute Treatment of Migraine: A Pilot Study of the Potential Impact of Preventive Therapy With TOPAMAX (Topiramate) Completed NCT00210496 Phase 4 topiramate; almotriptan malate
50 A Safety and Efficacy Study of BOTOX® in Korean Adults With Chronic Migraine Completed NCT02147561 Phase 4

Search NIH Clinical Center for Migraine with or Without Aura 1

Cochrane evidence based reviews: migraine disorders

Genetic Tests for Migraine with or Without Aura 1

Genetic tests related to Migraine with or Without Aura 1:

# Genetic test Affiliating Genes
1 Migraine 29 EDNRA ESR1 TNF

Anatomical Context for Migraine with or Without Aura 1

MalaCards organs/tissues related to Migraine with or Without Aura 1:

40
Brain, Testes, Cortex, Eye, Endothelial, Heart, Pituitary

Publications for Migraine with or Without Aura 1

Articles related to Migraine with or Without Aura 1:

(show top 50) (show all 30032)
# Title Authors PMID Year
1
MTHFR T677 homozygosis influences the presence of aura in migraineurs. 54 61 56
15154859 2004
2
Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. 61 56 54
15014183 2004
3
CGRP may play a causative role in migraine. 54 61 56
11993614 2002
4
The homozygous C677T mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for migraine. 61 54 56
11121176 2000
5
Genome-wide meta-analysis identifies new susceptibility loci for migraine. 61 56
23793025 2013
6
Spreading depression triggers headache by activating neuronal Panx1 channels. 56 61
23449592 2013
7
Shared genetic factors in migraine and depression: evidence from a genetic isolate. 56 61
20071666 2010
8
Trait components provide tools to dissect the genetic susceptibility of migraine. 61 56
16773568 2006
9
Familial risk of migraine: variation by proband age at onset and headache severity. 56 61
16476932 2006
10
Migraine and MTHFR C677T genotype in a population-based sample. 56 61
16365871 2006
11
Migraine with aura is a risk factor for unprovoked seizures in children. 56 61
16374824 2006
12
The estrogen receptor 1 G594A polymorphism is associated with migraine susceptibility in two independent case/control groups. 61 6
15133719 2004
13
Localization of a gene for migraine without aura to chromosome 4q21. 61 56
14513409 2003
14
Nuclear factor-kappaB as a molecular target for migraine therapy. 61 56
11921057 2002
15
A susceptibility locus for migraine with aura, on chromosome 4q24. 56 61
11836652 2002
16
Migraine without aura: a population-based twin study. 61 56
10514097 1999
17
Evidence of a genetic factor in migraine with aura: a population-based Danish twin study. 56 61
9989627 1999
18
Analysis of 31 families with an apparently autosomal-dominant transmission of migraine with aura in the nuclear family. 61 56
9259375 1997
19
Variation in migraine prevalence by race. 56 61
8710124 1996
20
Inheritance of migraine investigated by complex segregation analysis. 61 56
8522335 1995
21
Familial occurrence of migraine without aura and migraine with aura. 61 56
8392151 1993
22
Familial migraine in a Mexican population. 56 61
1608495 1992
23
Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. 61 56
1727198 1992
24
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. 56 61
1699472 1990
25
Segregation analysis of migraine in 128 families. 56 61
3527442 1986
26
Migraine and muscle contraction headaches: a continuum. 61 56
4019180 1985
27
Biochemical predisposition to dietary migraine: the role of phenolsulphotransferase. 61 56
6343297 1983
28
Migraine in twins. 61 56
859128 1977
29
MIGRAINE AND HEREDITY. 61 56
14322314 1965
30
Familiar occurrence of migraine headache: a study of heredity. 56 61
13196752 1954
31
Ubrogepant for the treatment of migraine. 42 61
32011192 2020
32
The functional alterations in primary migraine: A systematic review and meta-analysis protocol. 42 61
32150049 2020
33
Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. 42 61
32213509 2020
34
Antimigraine drug interactions with 5-hydroxytryptamine1A receptors. 56
2940961 1986
35
Migraine and coronary artery disease: an open study on the genetic polymorphism of the 5, 10 methylenetetrahydrofolate (MTHFR) and angiotensin I-converting enzyme (ACE) genes. 61 54
20518725 2010
36
Genetic bases of comorbidity between mood disorders and migraine: possible role of serotonin transporter gene. 54 61
19936882 2010
37
Dopamine: what's new in migraine? 61 54
20164768 2010
38
What have we learnt from triggering migraine? 54 61
20173638 2010
39
The PACAP receptor: a novel target for migraine treatment. 54 61
20430318 2010
40
CGRP receptor antagonism and migraine. 61 54
20430315 2010
41
Migraine and obesity: epidemiology, mechanisms, and implications. 61 54
19845784 2010
42
Calcitonin gene-related peptide: A molecular link between obesity and migraine? 54 61
20369076 2010
43
Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding. 61 54
20188075 2010
44
Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal. 61 54
20368903 2010
45
Single nucleotide polymorphisms of the serotonin transporter gene in migraine--an association study. 61 54
19845785 2010
46
Migraine models. 54 61
20336417 2010
47
A mutation in the first intracellular loop of CACNA1A prevents P/Q channel modulation by SNARE proteins and lowers exocytosis. 54 61
20080591 2010
48
Induction of multiple photophobic behaviors in a transgenic mouse sensitized to CGRP. 61 54
19607849 2010
49
The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. 61 54
19796656 2009
50
CGRP antagonists: hope for a new era in acute migraine treatment. 54 61
20120204 2009

Variations for Migraine with or Without Aura 1

ClinVar genetic disease variations for Migraine with or Without Aura 1:

6 (show all 17) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PPOX NM_001122764.3(PPOX):c.1353T>G (p.Tyr451Ter)SNV Pathogenic 523355 rs148292941 1:161140885-161140885 1:161171095-161171095
2 NOTCH3 NM_000435.3(NOTCH3):c.634T>C (p.Cys212Arg)SNV Pathogenic 812745 19:15302816-15302816 19:15192005-15192005
3 CAPN3 NM_000070.3(CAPN3):c.550del (p.Thr184fs)deletion Pathogenic 17621 rs80338800 15:42680001-42680001 15:42387803-42387803
4 BRCA2 NM_000059.3(BRCA2):c.4936_4939del (p.Glu1646fs)deletion Pathogenic 37935 rs80359473 13:32913425-32913428 13:32339288-32339291
5 CLCN1 NM_000083.3(CLCN1):c.950G>A (p.Arg317Gln)SNV Pathogenic/Likely pathogenic 17542 rs80356702 7:143027961-143027961 7:143330868-143330868
6 TAB2 NM_001292034.3(TAB2):c.1039C>T (p.Arg347Ter)SNV Likely pathogenic 373443 rs1057518422 6:149700090-149700090 6:149378954-149378954
7 ESR1 ESR1, 594G-ASNV risk factor 16591
8 NOTCH3 NM_000435.3(NOTCH3):c.1450T>G (p.Cys484Gly)SNV Likely pathogenic 523370 rs1555728965 19:15299088-15299088 19:15188277-15188277
9 MYH6 NM_002471.4(MYH6):c.3195G>C (p.Gln1065His)SNV Conflicting interpretations of pathogenicity 14149 rs267606904 14:23862177-23862177 14:23392968-23392968
10 DSP NM_004415.4(DSP):c.5218G>A (p.Glu1740Lys)SNV Conflicting interpretations of pathogenicity 44926 rs142885240 6:7581641-7581641 6:7581408-7581408
11 CAPN3 NM_000070.3(CAPN3):c.1746-20C>GSNV Conflicting interpretations of pathogenicity 92408 rs201892814 15:42695919-42695919 15:42403721-42403721
12 CACNA1A NM_001127222.2(CACNA1A):c.4174G>A (p.Val1392Met)SNV Conflicting interpretations of pathogenicity 195935 rs794727411 19:13372340-13372340 19:13261526-13261526
13 MYH6 NM_002471.3(MYH6):c.4594C>T (p.Arg1532Cys)SNV Conflicting interpretations of pathogenicity 239175 rs201827489 14:23856794-23856794 14:23387585-23387585
14 SLC2A1 NM_006516.3(SLC2A1):c.1407G>C (p.Gln469His)SNV Uncertain significance 374095 rs201748668 1:43392784-43392784 1:42927113-42927113
15 SCN5A NM_000335.5(SCN5A):c.892G>A (p.Gly298Ser)SNV Uncertain significance 9387 rs137854608 3:38651267-38651267 3:38609776-38609776
16 MAP2K2 NM_030662.3(MAP2K2):c.514A>G (p.Lys172Glu)SNV Uncertain significance 523536 rs1413580671 19:4102388-4102388 19:4102390-4102390
17 STIM1 NM_001277961.1(STIM1):c.1534T>A (p.Ser512Thr)SNV Uncertain significance 523431 rs1554971682 11:4107766-4107766 11:4086536-4086536

Copy number variations for Migraine with or Without Aura 1 from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 39736 10 118956999 118969809 Copy number KCNK18 Migraine

Expression for Migraine with or Without Aura 1

Search GEO for disease gene expression data for Migraine with or Without Aura 1.

Pathways for Migraine with or Without Aura 1

Pathways related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.88 NOTCH3 ESR1 ATP1A2

GO Terms for Migraine with or Without Aura 1

Biological processes related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to pain GO:0048265 9.26 CALCA CACNA1A
2 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.16 TNF ESR1
3 regulation of blood pressure GO:0008217 9.13 EDNRA CALCA ATP1A2
4 positive regulation of cytosolic calcium ion concentration GO:0007204 8.92 ESR1 EDNRA CALCA CACNA1A

Molecular functions related to Migraine with or Without Aura 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium ion binding GO:0031402 8.62 CAPN3 ATP1A2

Sources for Migraine with or Without Aura 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
4